




Lung cancer




CNS metastases



First-line treatments"



ALK inhibitors stop the ALK mutated protein from working, and **inhibit the growth and survival of the ALK+ cancer cell.**^{5,6}



Roche

Most patients progress on the current standard of care within one year of treatment, and approximately **60% will develop CNS metastases**.^{12,13}



A treatment which is active in the CNS can delay **development** and worsening

of CNS metastases.5



An effective treatment with the added benefit of CNS activity can prolong the time to disease progression.¹⁴



It is important to consider all these factors when deciding on the **best treatment for each individual patient**.



References

- 1. GLOBOCAN. [Internet, cited 2017 May 11] Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
- American Cancer Society [Internet, cited 2017 May 11] Available from: <u>https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html</u>.
- 3. Dearden S, et al. Ann Oncol 2013;24:2371-2376.
- 4. Choi YL, et al. Cancer Res 2008;68:4971-4976.
- 5. Roskoski Jr R, Pharmacol Res 2013;68:68-94.
- 6. Chia PL et al. Clin Epidemiol 2014;6:423-432
- 7. Takeuchi K, et al. Ann of Oncol 2016;27:185-192.
- 8. Gridelli C, et al. Cancer Treat Rev 2014;40:300-306.
- 9. Johung KL, et al. J Clin Oncol 2016;34(2):123-131.
- 10. Misra A, et al. J Pharm Pharm Sci 2003;6(2):252-273.
- 11. Lungcancer.org. [Internet, cited 2017 May 11] Available from: http://www.lungcancer.org/find_information/publications/163-lung_cancer_101/269-non-small_cell_lung_cancer_treatment.
- 12. Ghandi L, et al. J Clin Oncol 33, 2015(suppl; abstr 8019).
- 13. Shi W, Dicker A. J Clin Oncol 34, 2016;2 :107-109.
- 14. F. Hoffmann-La Roche Ltd. data on file.